Trial Profile
An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemorrhagic cystitis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 14 Apr 2015 New trial record